Article | October 30, 2023

Rapid Evolution: How DCTs' DNA Became Standard In Modern Clinical Trials

Source: Medable
Hey, Clinical Trial Study Teams - Let’s Go eTMF Mobile

It's undeniable how drastically clinical trials have evolved in the almost four years since the pandemic transformed the landscape of clinical research. Today, the digital and decentralized tools and technologies that enabled clinical trials to continue during the COVID-19 pandemic have become integral components of nearly all clinical trials, a significant departure from the dynamics of 2019.

Both the FDA and EMA have embraced capabilities that were originally categorized as "DCT (Decentralized clinical trials)." Earlier this year, these regulatory bodies issued long-awaited guidelines regarding decentralized clinical trials and their associated technologies.

As a result, cutting-edge clinical research technologies such as eConsent, eCOA, and telehealth are on the cusp of experiencing remarkable growth. Read the article below to learn how your teams can continue to advance in a pragmatic way.

access the Article!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.

Subscribe to Clinical Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Clinical Leader